Abbott Laboratories

NYSE:ABT Stock Report

Market Cap: US$198.1b

Abbott Laboratories Past Earnings Performance

Past criteria checks 4/6

Abbott Laboratories has been growing earnings at an average annual rate of 8.9%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 5.5% per year. Abbott Laboratories's return on equity is 14.4%, and it has net margins of 13.9%.

Key information

8.9%

Earnings growth rate

9.3%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate5.5%
Return on equity14.4%
Net Margin13.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Abbott Laboratories: A Future-Driven Pharma Brand With A Robust Pipeline

Dec 21

Calculating The Fair Value Of Abbott Laboratories (NYSE:ABT)

Dec 01
Calculating The Fair Value Of Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Investors Should Wait For A Pullback

Nov 25

Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist

Oct 31
Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist

Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation

Oct 21

Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event

Oct 14

Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?

Oct 11
Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?

Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price

Sep 27
Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price

Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change

Sep 11

A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Aug 16
A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Driving Value By Scaling Innovations

Aug 13

Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors

Aug 05

Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough

Jul 13

These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well

Jul 01
These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well

Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price

Jun 18
Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price

Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)

Jun 04
Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Why I Agree With Wall Street On This One

Jun 04

Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock

May 18

Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings

Apr 17

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Apr 15
Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now

Mar 21

Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger

Mar 19
Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger

Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly

Mar 06
Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly

Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024

Feb 27

Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon

Feb 08
Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon

Revenue & Expenses Breakdown

How Abbott Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:ABT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2441,2175,74410,9022,646
30 Jun 2440,7255,53510,7432,605
31 Mar 2440,3265,60810,5652,648
31 Dec 2340,1095,70110,3852,619
30 Sep 2339,9595,14210,5832,619
30 Jun 2340,2265,14010,6112,729
31 Mar 2341,5055,78510,6572,698
31 Dec 2243,6536,90510,7032,741
30 Sep 2245,0307,85710,9012,921
30 Jun 2245,5488,52010,9712,811
31 Mar 2244,5147,69510,9782,781
31 Dec 2143,0757,04211,0062,738
30 Sep 2142,3087,20810,5932,623
30 Jun 2140,2336,34310,2442,531
31 Mar 2137,3385,6939,8072,441
31 Dec 2034,6084,4499,5912,420
30 Sep 2032,2213,3469,4052,289
30 Jun 2031,4443,0739,4402,305
31 Mar 2032,0953,5399,5972,318
31 Dec 1931,9043,6669,5402,440
30 Sep 1931,3553,2729,4522,395
30 Jun 1930,9352,8679,4032,373
31 Mar 1930,7232,5829,4482,371
31 Dec 1830,5782,3199,5682,298
30 Sep 1830,4028029,4822,280
30 Jun 1829,5758129,1412,274
31 Mar 1828,4453658,8682,219
31 Dec 1727,3903448,8042,183
30 Sep 1725,1341,9718,1751,979
30 Jun 1723,6071,0557,8081,763
31 Mar 1722,3031,3847,3951,575
31 Dec 1620,8531,0566,5581,442
30 Sep 1620,7089896,6201,353
30 Jun 1620,5561,9396,6581,379
31 Mar 1620,3932,1246,6481,392
31 Dec 1520,4052,5866,7421,371
30 Sep 1520,5732,5236,5931,338
30 Jun 1520,5022,3656,5221,265
31 Mar 1520,3892,0046,4441,230
31 Dec 1420,2471,7106,3271,286
30 Sep 1419,9051,5606,3731,343
30 Jun 1419,6511,7626,3901,377
31 Mar 1419,0341,6546,1741,394
31 Dec 1319,6571,9706,3401,371

Quality Earnings: ABT has high quality earnings.

Growing Profit Margin: ABT's current net profit margins (13.9%) are higher than last year (12.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ABT's earnings have grown by 8.9% per year over the past 5 years.

Accelerating Growth: ABT's earnings growth over the past year (11.7%) exceeds its 5-year average (8.9% per year).

Earnings vs Industry: ABT earnings growth over the past year (11.7%) did not outperform the Medical Equipment industry 12.9%.

Return on Equity

High ROE: ABT's Return on Equity (14.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 01:42
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Abbott Laboratories is covered by 61 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Stephan GasteygerAtlantic Equities LLP
Ishan MajumdarBaptista Research